Changes in self-related cognitive processes and depressive symptom severity following a single, moderate dose of psilocybin in depressed patients

Paper. Belinger L, Moujaes F, von Rotz R et al.. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences, 10 Nov 2026.

Tags: Human, RCT, Psilocybin, Depression.

Weekly Science Digest, 6 Nov 2026 to 12 Nov 2026, finding 2: Three small trials, one shared mechanism: the self

Psilocybin and MDMA trials all landed on self-relating, but only one was blinded.

In 37 patients with major depression, a single 0.215 mg/kg psilocybin dose beat placebo on depression scores and raised positive self-concept at two weeks, with the two changes correlated. Twelve MDMA-treated depressed patients improved on alexithymia and self-compassion, and 20 adults with social anxiety improved on the Liebowitz scale against a waitlist.

How much weight it carries: One double-blind placebo-controlled trial (n=37) plus two open-label studies (n=12, n=20); the open-label arms cannot separate drug from expectancy. (Humans, RCT, Double-blind, Placebo-controlled, Brain imaging, Open-label, Small sample, n = 37)

Read the original

—
Node—
Statuslive
Throughput—